A phase II randomized controlled trial of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.
Androgen deprivation therapy
Cost-effectiveness
Exercise
Fatigue
Patient adherence
Physical fitness
Prostate cancer
Quality of life
Randomized controlled trial
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 Jan 2019
03 Jan 2019
Historique:
received:
12
05
2018
accepted:
05
12
2018
entrez:
5
1
2019
pubmed:
5
1
2019
medline:
16
4
2019
Statut:
epublish
Résumé
Existing evidence demonstrates that 1:1 personal training (PT) improves many adverse effects of androgen deprivation therapy (ADT). Whether less resource-intensive exercise delivery models are as effective remains to be established. We determined the feasibility of conducting a multi-center non-inferiority randomized controlled trial comparing PT with supervised group (GROUP) and home-based (HOME) exercise programs, and obtained preliminary efficacy estimates for GROUP and HOME compared to PT on quality of life (QOL) and physical fitness. Men with prostate cancer on ADT were recruited from one of two experienced Canadian centres and randomized 1:1:1 to PT, GROUP, or HOME. Randomization was stratified by length of ADT use and site. Participants completed moderate intensity aerobic and resistance exercises 4-5 days per week for 6 months with a target 150 min per week of exercise. Exercise prescriptions were individualized and progressed throughout the trial. Feasibility endpoints included recruitment, retention, adherence, and participant satisfaction. The efficacy endpoints QOL, fatigue, and fitness (VO2 peak, grip strength, and timed chair stands) in GROUP and HOME were compared for non-inferiority to PT. Descriptive analyses were used for feasibility endpoints. Between-group differences for efficacy endpoints were examined using Bayesian linear mixed effects models. Fifty-nine participants (mean age 69.9 years) were enrolled. The recruitment rate was 25.4% and recruitment was slower than projected. Retention was 71.2%. Exercise adherence as measured through attendance was high for supervised sessions but under 50% by self-report and accelerometry. Satisfaction was high and there was no difference in this measure between all three groups. Between-group differences (comparing both GROUP and HOME to PT) were smaller than the minimum clinically important difference on most measures of QOL, fatigue, and fitness. However, two of six outcomes for GROUP and four of six outcomes for HOME had a > 20% probability of being inferior for GROUP. Feasibility endpoints were generally met. Both GROUP and HOME interventions in men with PC on ADT appeared to be similar to PT for multiple efficacy outcomes, although conclusions are limited by a small sample size and cost considerations have not been incorporated. Efforts need to be targeted to improving recruitment and adherence. A larger trial is warranted. ClinicalTrials.gov: NCT02046837 . Date of registration: January 20, 2014.
Sections du résumé
BACKGROUND
BACKGROUND
Existing evidence demonstrates that 1:1 personal training (PT) improves many adverse effects of androgen deprivation therapy (ADT). Whether less resource-intensive exercise delivery models are as effective remains to be established. We determined the feasibility of conducting a multi-center non-inferiority randomized controlled trial comparing PT with supervised group (GROUP) and home-based (HOME) exercise programs, and obtained preliminary efficacy estimates for GROUP and HOME compared to PT on quality of life (QOL) and physical fitness.
METHODS
METHODS
Men with prostate cancer on ADT were recruited from one of two experienced Canadian centres and randomized 1:1:1 to PT, GROUP, or HOME. Randomization was stratified by length of ADT use and site. Participants completed moderate intensity aerobic and resistance exercises 4-5 days per week for 6 months with a target 150 min per week of exercise. Exercise prescriptions were individualized and progressed throughout the trial. Feasibility endpoints included recruitment, retention, adherence, and participant satisfaction. The efficacy endpoints QOL, fatigue, and fitness (VO2 peak, grip strength, and timed chair stands) in GROUP and HOME were compared for non-inferiority to PT. Descriptive analyses were used for feasibility endpoints. Between-group differences for efficacy endpoints were examined using Bayesian linear mixed effects models.
RESULTS
RESULTS
Fifty-nine participants (mean age 69.9 years) were enrolled. The recruitment rate was 25.4% and recruitment was slower than projected. Retention was 71.2%. Exercise adherence as measured through attendance was high for supervised sessions but under 50% by self-report and accelerometry. Satisfaction was high and there was no difference in this measure between all three groups. Between-group differences (comparing both GROUP and HOME to PT) were smaller than the minimum clinically important difference on most measures of QOL, fatigue, and fitness. However, two of six outcomes for GROUP and four of six outcomes for HOME had a > 20% probability of being inferior for GROUP.
CONCLUSIONS
CONCLUSIONS
Feasibility endpoints were generally met. Both GROUP and HOME interventions in men with PC on ADT appeared to be similar to PT for multiple efficacy outcomes, although conclusions are limited by a small sample size and cost considerations have not been incorporated. Efforts need to be targeted to improving recruitment and adherence. A larger trial is warranted.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov: NCT02046837 . Date of registration: January 20, 2014.
Identifiants
pubmed: 30606137
doi: 10.1186/s12885-018-5189-5
pii: 10.1186/s12885-018-5189-5
pmc: PMC6318980
doi:
Substances chimiques
Androgen Antagonists
0
Antineoplastic Agents, Hormonal
0
Banques de données
ClinicalTrials.gov
['NCT02046837']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
2Subventions
Organisme : Prostate Cancer Canada
ID : D2013-1
Références
Eur Urol. 2016 Apr;69(4):693-703
pubmed: 26632144
Can J Appl Sport Sci. 1985 Sep;10(3):141-6
pubmed: 4053261
J Pain Symptom Manage. 2012 Jan;43(1):96-110
pubmed: 21640547
Qual Life Res. 2007 Apr;16(3):509-22
pubmed: 17091359
N Engl J Med. 2016 Jul 14;375(2):154-61
pubmed: 27410924
Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):647-57
pubmed: 21335510
JAMA. 2005 Jul 13;294(2):238-44
pubmed: 16014598
Support Care Cancer. 2008 Sep;16(9):987-97
pubmed: 18274783
Qual Life Res. 2002 May;11(3):207-21
pubmed: 12074259
Cancer Res. 2011 Jun 1;71(11):3889-95
pubmed: 21610110
Support Care Cancer. 2012 Feb;20(2):221-33
pubmed: 21989678
JAMA. 2015 Feb 3;313(5):459-60
pubmed: 25569175
Int J Behav Nutr Phys Act. 2008 Nov 06;5:56
pubmed: 18990237
Clin Genitourin Cancer. 2013 Dec;11(4):375-84
pubmed: 23891497
J Sport Exerc Psychol. 2007 Feb;29(1):118-27
pubmed: 17556779
Can J Public Health. 1986 Sep-Oct;77(5):359-62
pubmed: 3791117
J Clin Epidemiol. 2004 Jun;57(6):571-9
pubmed: 15246125
J Clin Oncol. 2009 Jan 20;27(3):344-51
pubmed: 19064985
Med Sci Sports Exerc. 2007 Sep;39(9):1509-14
pubmed: 17805082
Cancer Med. 2016 May;5(5):787-94
pubmed: 26872005
Arch Phys Med Rehabil. 1985 Feb;66(2):69-74
pubmed: 3970660
Urol Oncol. 2011 Nov-Dec;29(6):647-53
pubmed: 19926311
Chest. 2001 Jan;119(1):256-70
pubmed: 11157613
BMC Med Res Methodol. 2010 Jan 06;10:1
pubmed: 20053272
J Clin Oncol. 2012 Sep 10;30(26):3297-303
pubmed: 22649133
Urology. 1997 Dec;50(6):920-8
pubmed: 9426724
J Clin Oncol. 2010 Dec 1;28(34):5038-45
pubmed: 21041715
Int J Public Health. 2013 Dec;58(6):949-53
pubmed: 23974352
Med Sci Sports Exerc. 1998 May;30(5):777-81
pubmed: 9588623
Psychooncology. 2006 Oct;15(10):847-62
pubmed: 16447306
Crit Rev Oncol Hematol. 2006 Dec;60(3):201-15
pubmed: 16860998
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Qual Life Res. 1999 Sep;8(6):539-49
pubmed: 10548869
J Aging Phys Act. 2013 Oct;21(4):455-78
pubmed: 23238110
BJU Int. 2008 Jul;102(1):44-7
pubmed: 18336606
Curr Sports Med Rep. 2013 Jul-Aug;12(4):215-7
pubmed: 23851406
Leuk Res. 2015 Aug 28;:
pubmed: 26350143
J Clin Oncol. 2010 Jan 10;28(2):340-7
pubmed: 19949016
Semin Hematol. 1997 Jul;34(3 Suppl 2):13-9
pubmed: 9253779
BMC Cancer. 2015 Apr 25;15:312
pubmed: 25908311
J Clin Epidemiol. 2012 Mar;65(3):301-8
pubmed: 22169081
Percept Mot Skills. 1995 Feb;80(1):163-6
pubmed: 7624188
J Clin Oncol. 2003 May 1;21(9):1653-9
pubmed: 12721238